Genenta Science, a Milan, Italy-based biotech company focused on hematopoietic stem cell gene therapy, added Tiziana Mattioni, Ph.D. as its Chief Operating Officer.
Dr. Mattioni comes to Genenta Science from Merck Serono, a division in Merck KGaA – Germany, where she most recently served as Director Global Program Leader in Oncology.
At Merck Serono, dr. Mattioni led the development of Cancer Vaccines and Anti-angiogenic drugs.
Prior to the position as a leader in oncology, she held roles in Clinical Trial Operations and Medical Safety (pharmacovigilance)
Co-founded the Pierluigi Paracchi, Chairman and Chief Executive Officer, Luigi Naldini – Director of the San Raffaele-Telethon Institute for Gene Therapy, TIGET and of the Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Hospital; Professor of Histology and of Gene and Cell Therapy, San Raffaele University, and Bernhard Gentner, Haematologist and Physician Scientist at the San Raffaele Hospital and TIGET, Genenta Science develops a gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages.
The company recently closed a €10M (approx. $11.2m) Series A funding round.